Omalizumab, the first available antibody for biological treatment of severe asthma: more than a decade of real-life effectiveness

Omalizumab was the first, and for a long time the only available monoclonal antibody for the add-on treatment of severe allergic asthma. In particular, omalizumab selectively targets human immunoglobulin (Ig)E, forming small-size immune complexes that inhibit IgE binding to its high- and low-affinit...

Full description

Bibliographic Details
Main Authors: Corrado Pelaia, Cecilia Calabrese, Rosa Terracciano, Francesco de Blasio, Alessandro Vatrella, Girolamo Pelaia
Format: Article
Published: SAGE Publishing 2018-11-01
Series:Therapeutic Advances in Respiratory Disease
Online Access: